27Apr
[Video] Six Things You Need to Know About Life Sciences M&A During and After COVID-19
While life sciences M&A activity soared to a new high in 2019, the uncertainty surrounding the pandemic has led to a slow down in deal making activity. However, as the crisis in the U.S. subsides and the U.S. economy stabilizes, we expect life...
By:
Arnall Golden Gregory LLP
Related
The ongoing Scottish case of Serco Limited v Forth Health Limited highlights the difficulties that c...
Read More >
The US Food and Drug Administration (FDA or the Agency) on June 11 issued the final guidance: “Prem...
Read More >
The U.S. Department of Transportation’s Federal Motor Carrier Safety Administration (FMCSA) has pub...
Read More >
From the initial real estate purchase to completing construction, the entire real estate industry ha...
Read More >
As expected, the US Department of Labor issued a new final rule on FLSA overtime exemptions this wee...
Read More >
In our ever-increasing multi-multinational workforce that seems to rely more heavily on foreign labo...
Read More >